FI874706A0 - Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon- - Google Patents

Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon-

Info

Publication number
FI874706A0
FI874706A0 FI874706A FI874706A FI874706A0 FI 874706 A0 FI874706 A0 FI 874706A0 FI 874706 A FI874706 A FI 874706A FI 874706 A FI874706 A FI 874706A FI 874706 A0 FI874706 A0 FI 874706A0
Authority
FI
Finland
Prior art keywords
pharmaceutical compositions
stable pharmaceutical
preparation
recombinant interferon
glycosylated recombinant
Prior art date
Application number
FI874706A
Other languages
English (en)
Finnish (fi)
Other versions
FI95002B (sv
FI95002C (sv
FI874706A (sv
Inventor
Ze Ev Shaked
Tracy Stewart
Jody Thomson
James William Thomson
Terrance Taforo
Susan Hershenson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of FI874706A0 publication Critical patent/FI874706A0/sv
Publication of FI874706A publication Critical patent/FI874706A/sv
Publication of FI95002B publication Critical patent/FI95002B/sv
Application granted granted Critical
Publication of FI95002C publication Critical patent/FI95002C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI874706A 1986-10-27 1987-10-26 Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon- FI95002C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92342386A 1986-10-27 1986-10-27
US92342386 1986-10-27

Publications (4)

Publication Number Publication Date
FI874706A0 true FI874706A0 (sv) 1987-10-26
FI874706A FI874706A (sv) 1988-04-28
FI95002B FI95002B (sv) 1995-08-31
FI95002C FI95002C (sv) 1995-12-11

Family

ID=25448670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI874706A FI95002C (sv) 1986-10-27 1987-10-26 Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon-

Country Status (9)

Country Link
EP (1) EP0270799B1 (sv)
JP (1) JPS63179833A (sv)
AT (1) ATE111744T1 (sv)
AU (2) AU8019187A (sv)
CA (1) CA1294215C (sv)
DE (1) DE3750574T2 (sv)
DK (1) DK563487A (sv)
FI (1) FI95002C (sv)
NO (1) NO175704C (sv)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
JPH10504441A (ja) 1994-03-07 1998-05-06 カイロン コーポレイション Ｔｎｆ形成阻害のための組成物およびその使用
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ES2181281T5 (es) 1997-09-23 2008-04-16 Rentschler Biotechnologie Gmbh Formulaciones liquidas de interferon beta.
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
AU2002230707B2 (en) 2000-11-07 2006-08-24 Novartis Vaccines And Diagnostics, Inc. Stabilized interferon compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
EP2236172A1 (en) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PT1694360E (pt) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
US20070218060A1 (en) 2003-11-04 2007-09-20 Chiron Corporation Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
EP3338798A1 (en) 2011-01-06 2018-06-27 Bionor Immuno AS Multimeric peptide
EA201492262A1 (ru) 2012-06-06 2015-08-31 Бионор Иммуно Ас Конструкция пептидного каркаса
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CN105263390A (zh) 2013-04-23 2016-01-20 雪松-西奈医学中心 用于从荧光团同时录制可见光图像和红外光图像的***和方法
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
ES2960601T3 (es) 2014-06-12 2024-03-05 Cedars Sinai Medical Center Composiciones y métodos para el tratamiento del cáncer
JP6426288B2 (ja) 2014-07-22 2018-11-21 レモネックス インコーポレイテッドLemonex Inc. 生理活性物質又はタンパク質伝達用組成物及びその用途
WO2016073647A2 (en) 2014-11-04 2016-05-12 University Of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
EP3800199A1 (en) 2015-05-05 2021-04-07 The Regents of The University of California H3.3 ctl peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
FI126979B (sv) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyofiliserad farmaceutisk formulering och användning därav
MX2019009271A (es) 2017-02-06 2019-10-30 Lemonex Inc Portador de sustancia fisiologicamente activa.
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
WO2019023245A1 (en) 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
AU2019254726B2 (en) * 2018-04-19 2022-10-06 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
US20210395358A1 (en) 2018-11-08 2021-12-23 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
EP3897718A4 (en) 2018-12-20 2022-09-14 Cedars-Sinai Medical Center CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED ORGAN TRANSPLANT REJECTION
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55102519A (en) * 1979-01-31 1980-08-05 Green Cross Corp:The Stabilization of interferon
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
ATE52693T1 (de) * 1982-10-25 1990-06-15 Genentech Inc Synergistische humaninterferonaktivitaet.
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物

Also Published As

Publication number Publication date
NO874445L (no) 1988-04-28
EP0270799B1 (en) 1994-09-21
CA1294215C (en) 1992-01-14
FI95002B (sv) 1995-08-31
EP0270799A1 (en) 1988-06-15
AU1063392A (en) 1992-03-19
NO175704C (no) 1994-11-23
AU8019187A (en) 1988-04-28
DE3750574D1 (de) 1994-10-27
DK563487D0 (da) 1987-10-27
DK563487A (da) 1988-04-28
JPS63179833A (ja) 1988-07-23
NO874445D0 (no) 1987-10-26
ATE111744T1 (de) 1994-10-15
AU659127B2 (en) 1995-05-11
FI95002C (sv) 1995-12-11
DE3750574T2 (de) 1995-02-02
FI874706A (sv) 1988-04-28
NO175704B (no) 1994-08-15

Similar Documents

Publication Publication Date Title
FI874706A0 (sv) Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon-
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
DE68924491T2 (de) Intrascheidenabgabe von aktiven Polypeptiden.
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
EP0217645A3 (en) Stable formulation of biologically active proteins for parenteral injection
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
SE8402560L (sv) Farmaceutisk komposition
DK0759775T3 (da) Flydende IFN-beta-formuleringer
DE3854290D1 (de) Stabilisierung von therapeutisch wirksamen Proteinen in pharmazeutischen Zubereitungen.
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
ES2073063T3 (es) Formulaciones galenicas acuosas de eritropoyetina y su uso.
IT8522442A0 (it) Derivati nucleosidici aventi proprieta' antierpetiche, composizioni farmaceutiche che licontengono e procedimento per lapreparazione degli ingredienti attivi.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: CETUS CORPORATION

MA Patent expired